Aromatase inhibitors and bone loss

ONCOLOGY

Volumn 20, Issue 9, 2006, Pages 1029-1039

  Perez, Edith A ^a   Serene, M ^a   Durling, Frances C ^a   Weilbaecher, Katherine ^b  

^a MAYO CLINIC   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANASTROZOLE; ANDROSTENEDIONE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; DENOSUMAB; DOXORUBICIN; ESTROGEN RECEPTOR; ETIDRONIC ACID; EXEMESTANE; FLUOROURACIL; GONADORELIN; GONADORELIN AGONIST; GOSERELIN; IBANDRONIC ACID; LETROZOLE; METHOTREXATE; PAMIDRONIC ACID; PLACEBO; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; VITAMIN D; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

ABDOMINAL PAIN; ADJUVANT THERAPY; AMENORRHEA; ARTHRALGIA; BACKACHE; BONE DENSITOMETRY; BONE DISEASE; BONE METASTASIS; BONE MINERAL LOSS; BONE MINERALIZATION; BONE NECROSIS; BONE PAIN; BONE TURNOVER; BREAST CANCER; CANCER RECURRENCE; CHILL; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DIARRHEA; DIET THERAPY; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BINDING; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; DYSPEPSIA; DYSPHAGIA; ESOPHAGITIS; ESOPHAGUS ULCER; EXERCISE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; FRACTURE; FRAGILITY FRACTURE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HIP FRACTURE; HUMAN; HYPERCALCEMIA; IN VITRO STUDY; IN VIVO STUDY; INFECTION; JAW OSTEONECROSIS; KIDNEY FUNCTION; LIFESTYLE MODIFICATION; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEPHROTOXICITY; NONHUMAN; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; OVARIECTOMY; PATHOGENESIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; PREMATURE OVARIAN FAILURE; PROPHYLAXIS; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCREENING TEST; SIDE EFFECT; SMOKING CESSATION; TREATMENT DURATION; VERTEBRA DISLOCATION; VITAMIN INTAKE; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; FEMALE;

AROMATASE INHIBITORS; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; BREAST NEOPLASMS; FEMALE; HUMANS;

EID: 34248172819     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Winer EP, Hudis C, Burstein HJ, et al: American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004. J Clin Oncol 23:619-629, 2005.
2. American Cancer Society: Breast Cancer Facts & Figures 2005-2006. Available at www.cancer.org. Accessed July 12, 2006.
3. Osborne C, Tripathy D: Aromatase inhibitors: Rationale and use in breast cancer. Ann Rev Med 56:103-116, 2005.
4. Mincey BA, Perez EA: Aromatase inhibitors and bone health, in ASCO 2005 Education Book, pp 27-34. 41st Annual Meeting, Orlando, Florida, 2005.
5. Goss PE, Strasser-Weippl K: Prevention strategies with aromatase inhibitors. Clin Cancer Res 10(suppl):372s-379s, 2004.
6. Hofbauer LC, Schoppet M: Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 292:490-495, 2004.
7. Raisz LG: Pathogenesis of osteoporosis: Concepts, conflicts and prospects. J Clin Invest 115:3318-3325, 2005.
8. Blair JM, Zhou H, Seibel MJ, et al: Mechanisms of disease: Roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis. Nat Prac Clin Oncol 3(1):41-49, 2006.
9. Riggs BL, Khosla S, Melton LJ, III: Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 23:279-302, 2002.
10. Benito M, Gomberg B, Wehrli FW, et al: Deterioration of trabecular architecture in hypogonadal men. J Clin Endocrinol Metab 88:1497-1502, 2003.
11. Pfeilschifter J, Diel IJ: Osteoporosis due to cancer treatment: Pathogenesis and management. J Clin Oncol 18:1570-1593, 2000.
12. Kanis JA: Pathogenesis of osteoporosis and fracture, in Kanis JA (ed): Osteoporosis, pp 22-55. London, Blackwell Healthcare Communications, 1997.
13. Eastell R, Hannon RA, Cuzick J, et al: Effect of anastrozole on bone density and bone turnover: Results of the 'Arimidex' (anastrozole), Tamoxifen, Alone or in Combination (ATAC) Study (abstract 1170). J Bone Miner Res 17(suppl 1):S165, 2002.
14. Gnant M, Jakesz R, Mlineritsch B, et al: Zoledronic acid effectively counteracts cancer treatment induced bone loss (CTIBL) in premenopausal breast cancer patients receiving adjuvant endocrine treatment with goserelin plus anastrozole versus goserelin plus tamoxifen - Bone density subprotocol results of a randomized multicenter trial (ABCSG-12) (abstract 6). Presented at the 27th Annual San Antonio Breast Cancer Symposium, December 8, 2004.
15. Shapiro CL, Manola J, Leboff M: Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 19:3306-3311, 2001.
16. Cummings SR, Bates D, Black DM: Clinical use of bone densitometry: Scientific review. JAMA 288:1889-1897, 2002.
17. Actonel (risedronate sodium tablets) prescribing information. Cincinnati, Procter & Gamble, 2005.
18. Garnero P, Sornay-Rendu E, Chapuy MC, et al: Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 11:337-349, 1996.
19. Demers LM, Costa L, Lipton A: Biochemical markers and skeletal metastases. Clin Orthop Relat Res Oct(415 suppl):S138-S147, 2003.
20. Heshmati HM, Khosla S, Robins SP, et al: Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women. J Bone Miner Res 17:172-178, 2002.
21. Brown JE, Cook RJ, Major P, et al: Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97:59-69, 2005.
22. Lipton A, Hei YJ, Coleman RE, et al: Normalization of urinary N-telopeptide levels by zoledronic acid correlates with improved survival in patients with bone metastases from breast cancer (abstract 3015). Presented at the 28th Annual San Antonio Breast Cancer Symposium, December 8-11, 2005.
23. Brufsky A, Harker WG, Beck JT, et al: Zoledronic acid (ZA) effectively inhibits cancer treatment-induced bone loss (CTIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (Let): 12-month BMD results of the Z-FAST trial (abstract 533). Proc Am Soc Clin Oncol 23:12S, 2005.
24. Hillner BE, Ingle JN, Chlebowski RT: American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21:4042-4057, 2003.
25. National Osteoporosis Foundation: Physician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC, National Osteoporosis Foundation, 2003. Available at http://www.nof.org
26. Baum M, Buzdar A, Cuzick J, et al: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98:1802-1810, 2003.
27. Howell A, Cuzick J, Baum M, et al, for the ATAC Trialists' Group: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365:60-62, 2005.
28. Coleman RE, on behalf of the ATAC Trialists' Group: Effect of anastrozole on bone mineral density: 5-year results from the 'Arimidex,' Tamoxifen, Alone or in Combination (ATAC) trial (abstract 511). J Clin Oncol 24(suppl 18S):5s, 2006.
29. Goss PE, Ingle JN, Martino S, et al: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793-1802, 2003.
30. Goss PE, Ingle JN, Martino S, et al: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97:1262-1271, 2005.
31. Perez EA, Josse RG, Pritchard KI, et al: Effect of letrozole vs placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: A companion study to NCIC CTG MA.17. J Clin Oncol 24(22):3629-3635, 2006.
32. Thurlimann BJ, Keshaviah A, Coates AS, et al: A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. The Breast International Group (BIG) 1-98 Collaborative Group. N Engl J Med 353:2747-2757, 2005.
33. Jakesz R, Jonat W, Gnant M, et al: Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366:455-462, 2005.
34. Coombes RC, Hall E, Gibson LJ, et al: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081-1092, 2004.
35. Coleman RE, Banks LM, Hall E, et al, for the Intergroup Exemestane Study: Intergroup Exemestane Study: 1 year results of the bone sub-protocol (abstract 401). Presented at the 27th Annual San Antonio Breast Cancer Symposium, December 10, 2004.
36. Lonning PE, Geisler J, Krag LE, et al: Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 23:5126-5137, 2005.
37. Lonning PE, Geisler J, Krag LE, et al: Changes in bone metabolism after 2 years' treatment with exemestane (E) in postmenopausal women with early breast cancer (EBC) at low risk: Follow-up (FU) results of a randomized placebo-controlled study (abstract 531). Proc Am Soc Clin Oncol 23:11s, 2005.
38. Reszka AA, Rodan GA: Bisphosphonate mechanism of action. Curr Rheumatol Rep 5:65-74, 2003.
39. Green JR, Müller K, Jaeggi KA: Preclinical pharmacology of CGP 42¢446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 745-751, 1994.
40. Saarto T, Blomqvist C, Valimaki M, et al: Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: A randomized study in premenopausal breast cancer patients. J Clin Oncol 15:1341-1347, 1997.
41. Vehmanen L, Saarto T, Risteli J, et al: Short-term intermittent intravenous clodronate in the prevention of bone loss related to chemotherapy-induced ovarian failure. Breast Cancer Res Treat 87:181-188, 2004.
42. Delmas PD, Balena R, Confravreux E, et al: Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: A double-blind, placebo-controlled study. J Clin Oncol 15:955-962, 1997.
43. Ripps BA, VanGilder K, Minhas B, et al: Alendronate for the prevention of bone mineral loss during gonadotropin-releasing hormone agonist therapy. J Reprod Med 48:761-766, 2003.
44. Smith MR, McGovern FJ, Zietman AL, et al: Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med. 345:948-955, 2001.
45. Mincey BA, personal communication.
46. Fosamax (alendronate sodium) tablets prescribing information. Whitehouse Station, NJ, Merck, 2005.
47. Boniva (ibandronate sodium) tablets complete product information. Nutley, NJ, Roche, 2005.
48. Zometa (zoledronic acid) injection prescribing information. East Hanover, NJ, Novartis, 2005.
49. Pamidronate (disodium) for injection prescribing information. Bedford, Ohio, Bedford Laboratories, 2001.
50. Caro JJ, Ishak KJ, Huybrechts KF, et al: The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int [serial online] May 27, 2004.
51. Ruggiero SL, Gralow J, Marx RE, et al: Practical guidelines for the prevention, diagnosis and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract 2:7-14, 2006.
52. Durie BGM, Katz M, Crowley J: Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353:99-102, 2005.
53. Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23:8580-8587, 2005.
54. Bekker, PJ, Holloway DL, Rasmussen AS, et al: A single dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 19:1059-1066, 2004.
55. Available at www.clinicaltrials.gov. Accessed July 12, 2006.
56. Lipton A, Alvarado C, DeBoer R, et al: Randomized, active-controlled study of denosumab (AMG 162) in breast cancer patients with bone metastases not previously treated with IV bisphosphonates (abstract 512). J Clin Oncol 24(suppl 18S):6s, 2006.
57. Mincey BA, Duh MS, Thomas SK, et al: Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors. Clin Breast Cancer 7(2):127-132, 2006.
58. National Comprehensive Cancer Network: Clinical practice guidelines in oncology. Breast cancer v.2.2005. Available at www.nccn.org. Accessed July 12, 2006.
59. Nieves J: Nutrition, in Cummings SR, Cosman F, Jamal SA (eds): Osteoporosis: An Evidence-Based Guide to Prevention and Management, pp 85-108. Philadelphia, American College of Physicians, 2002.
60. Holick MF: Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am J Clin Nutr 79:362-371, 2004.
61. Zinaman RS, Van Poznak CH, Goldberg LM, et al: Supplemental calcium and vitamin D intake of women with early stage breast cancer (abstract 4006). Presented at the 27th Annual San Antonio Breast Cancer Symposium, December 10, 2004.
62. Rubin C, Recker R, Cullen D, et al: Prevention of postmenopausal bone loss by a low-magnitude, high-frequency mechanical stimuli: A clinical trial assessing compliance, efficacy, and safety. J Bone Miner Res 19:343-351, 2004.
63. Chen Z, Maricic M, Bassford TL, et al: Fracture risk among breast cancer survivors results from the Women's Health Initiative Observational Study. Arch Intern Med 165:552-558, 2005.